Psychother Psychosom. 2025 Oct 20:1-32. doi: 10.1159/000548961. Online ahead of print.

ABSTRACT

INTRODUCTION: Obsessive-compulsive disorder (OCD) is a chronic condition where many patients remain symptomatic despite first-line treatments such as Cognitive Behavioural Therapy and selective serotonin reuptake inhibitors. This randomised controlled trial evaluated Mindfulness-Based Cognitive Therapy (MBCT) efficacy as an augmentation strategy and its impact on brain functional connectivity.

METHODS: Sixty-eight participants with moderately symptomatic OCD were randomised into MBCT or Treatment as Usual (TAU). Clinical outcomes were evaluated using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the Obsessive-Compulsive Inventory, alongside other relevant secondary outcomes. Data were analysed using repeated measures ANOVA to assess time * group effects. Neuroimaging functional measures (resting-state network-connectivity), were collected before and after the intervention and analysed using independent component analysis.

RESULTS: Primary outcome: MBCT significantly reduced OCD symptoms compared to TAU (31.73% vs. 8.07% Y-BOCS reduction).

SECONDARY OUTCOMES: MBCT group also experienced reductions in depressive symptoms, rumination, perceived stress and quality of life. No significant post-treatment changes were observed in resting-state connectivity. However, baseline connectivity demonstrated significant predictive value, with lower connectivity in pre-selected networks of interest, including the fronto-striatal, salience, and default-mode networks, associated with greater reductions in Y-BOCS scores.

CONCLUSION: MBCT is an effective strategy for individuals with moderately symptomatic OCD who continue to experience symptoms despite prior gold-standard treatments. While no post-treatment changes in brain functional connectivity were observed, baseline connectivity patterns predicted symptom reduction, suggesting a neural basis for MBCT response. Trial name: Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients. ID number: NCT03128749.

PMID:41115123 | DOI:10.1159/000548961